未如实提供证据，四家药企因阻碍反垄断调查各被罚20万元

Core Viewpoint - Four pharmaceutical companies were fined 200,000 yuan each for obstructing an antitrust investigation related to magnesium trisilicate raw materials [1][3]. Group 1: Companies Involved - The companies involved in the antitrust case are Shanghai Qingping Pharmaceutical Co., Ltd., Chongqing Mingbo Pharmaceutical Co., Ltd., Weifang Longhai Cheng Pharmaceutical Co., Ltd., and Weifang Jinkaisheng Pharmaceutical Co., Ltd. [1] - These companies had business dealings with Weifang Zhongyuan Pharmaceutical Co., Ltd., which was found to have abused its dominant market position from 2014 to September 2019 [1]. Group 2: Investigation Findings - Weifang Zhongyuan was penalized approximately 37.65 million yuan for unfair pricing, refusal to trade, and imposing unreasonable trading conditions [1]. - During the initial investigation, Shanghai Qingping denied any rebate payments to Weifang Zhongyuan but later admitted to such payments by March 2021 [2]. - Chongqing Mingbo initially denied receiving monopoly profits but later acknowledged that their sales were merely for documentation purposes, returning the sales revenue to Weifang Zhongyuan [2]. - Weifang Jinkaisheng also retracted previous statements made during the investigation, claiming their transactions were not monopolistic [2]. Group 3: Legal Framework - According to the previous Antitrust Law, companies are required to cooperate with antitrust investigations, and failure to do so can result in fines of up to 200,000 yuan for companies [3]. - The actions of the four pharmaceutical companies in submitting false evidence and obstructing the investigation were deemed to waste enforcement resources and hinder normal administrative processes [3].